There is a number of industry opinion leaders among our experts. Take a look at the listed resourses to find out more
Clinical Research in Eastern Europe Articles
Irina Petrova, Director of Clinical Operations for OCT Clinical Trials, explores why U.S. and other international companies are turning to Russia as a clinical research destination.
Why do US sponsors come to Russia? Discover new options for clinical trialsWebinar
Find out why more than 50% of studies initiated in Russia are conducted by foreign sponsors with the US in the lead. Key experts from one of the major local CROs in Eastern Europe will share exclusive insights on 3 critical benefits of the region to advance your clinical strategy.
Interim Analysis as a Key Decision-Making ToolArticles
Good Clinical Practice dictates stricter compliance with the fundamental concepts of conducting interim analysis by Russian pharmaсeutical companies, mainly because of the additional organizational resources it requires. On the other hand, the methodology and principles of deciding on the necessity of carrying out an interim analysis are not always properly reflected in a research protocol.
Russia Opens the Door for Stem Cell Clinical TrialsArticles
While the US, Europe and some Asian countries have had a fully functional, comprehensive regulatory platform for BCP procedures for over two decades, Russia is relatively new to the area, only recently approving a regulatory framework.
Patterns of collaboration between medical writers and biostatisticians Articles
The Russian clinical trial industry and Russia’s local regulatory requirements are developing rapidly. Within Russian contract research organisations, medical writers must take on non-traditional roles and, in particular, must collaborate closely with biostatisticians within their organizations.
Bioequivalence study of a drug for HIV patientsCase
An open-label, randomize, two-period, crossover study in healthy volunteers. Over 90% of volunteers were enrolled during the first two weeks. The target enrollment rates were reached within 21 days
Nonclinical studies in the Russian FederationArticles
Drug product developers and sponsors face a number of problems when organizing a nonclinical study in Russia, especially, the diverse range of standards and few certified animal breeding centers, complicating adaptation of the available experimental data to domestic legislation.
* - Required fields